Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459351 | 1.00 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL376934 | 0.91 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL376932 | 0.91 | PSEN1 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7902802 | 0.89 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL377208 | 0.87 | BMP1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL377206 | 0.87 | BMP1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL458597 | 0.82 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL458595 | 0.82 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL376699 | 0.79 | TP53 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL376701 | 0.79 | TP53 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102361862-A | Thiophenyl sulfonamides for the treatment of alzheimer's disease | BRISTOL MYERS SQUIBB CO | 2012-02-22 | — | — | CN | claimed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | claimed |
| EP-2408760-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-24 | — | — | US | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107997-A1 | THIOPHENYL SULFONAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071199-A1 | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease | APP, PSEN1, PSEN2 | PSEN1 2/4885PSEN2 3/4885APH1B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.